Machine learning algorithms can improve the drug development process by enabling greater control and accuracy by finding targeted patients. At Dascena, we collaborate with biopharma companies to enable smaller, shorter trials.
Dascena developed an algorithm that helped Takeda link reductions in a surrogate endpoint (ΔGRV) to improvements in patient outcome (mortality).
This result helped Takeda determine development next steps by tying existing surrogate endpoint results to clinical probability of success.
Dascena developed an algorithm that used readily available EHR data to identify patients most at risk for Pulmonary Hypertension (PH) and Pulmonary Arterial Hypertension (PAH).
Dascena’s algorithm accurately predicted 80% of PH patients 12 months before diagnosis.